The clinical study will be led by Mr Yasuo KURIMOTO, Director of Ophtalmology at Kobe City Medical Center, and Mrs Masayo TAKAHASHI of RIKEN. In the study, a suspension of retinal pigment epithelium (RPE) cells derived from other iPS cells will be transplanted. The patients will be between 50 and 85 years old.

RIKEN CDB news release, February 8, 2017